

P No	Cancer Type	Dose (mg)	Initial Tumor Lesion (mm)	C2 D21*	C4 D21	C6 D21	C8 D21	C10 D21	C12 D21	C14 D21	C16 D21	C18 D21	C20 D21	C22 D21	Biomarker
23	Nasopharyngeal cancer + tongue cancer	14	42.1	↓7% SD	Drop										FGF3/4/19 amplification
25	lower jawbone ameloblastic carcinoma	16	77.1	↓33.5 PR	↓42.7% PR	↓41.8% PR	↓40% PR	↓44.4% PR	↓47.6% PR	↓48% PR	↓48% PR	↓48.7% PR	↓47.6% PR	↓45.4% PR	FGFR2 mutation
28	Laryngeal cancer	16	77.9	↓2.7% SD	↑6% SD	↑7.7% SD	Drop								FGF3/4/19 amplification
32	Right upper jaw ameloblastoma	16	51.2	↑21.8% PD	NA										FGFR2 mutation
34	Nasopharyngeal carcinoma	18	29	↓8% SD	↓27.9% SD	↓25.8% SD	↓26.6% SD	↓35.5% PR							FGFR1 mutation
37	Tongue Squamous cell carcinoma	18	53.3	↓33.8% PR	↓30% PR	↓25.7% SD	↓37% PR								FGF3/4/6/12/19/23 amplification
38	Left pharyngeal squamous cell carcinoma	22	33.6	↓7.7% SD	↓14.6% SD	↓14.9% SD									FGF3/4/19 amplification

*C2D21 means Cycle 2, Day 21; C4D21 means Cycle 4, Day 21, etc.

FIG. 1